PIA
ITCI

Piedmont Investment Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Piedmont Investment Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-778
Closed -$14K – 2364
2018
Q2 		$14K Buy
+778
New +$15.8K ﹤0.01% 1720

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Piedmont Investment Advisors's ITCI Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2018, closing a stake of 778 shares — an estimated $14K sold.

Piedmont Investment Advisors first reported a position in ITCI in Q2 2018 and held it in 1 quarter. The position peaked at $14K in Q2 2018. 131 funds tracked by Wall St. Rank hold ITCI as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 778 Intra-Cellular Therapies Inc. shares in Q3 2018, an estimated $14K.
  • Piedmont Investment Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Intra-Cellular Therapies Inc. position peaked at $14K in Q2 2018.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.